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Abstract
Background: Elevated levels of matrix metalloproteinases have been found to associate with poor prognosis in
various carcinomas. This study aimed at evaluating plasma levels of MMP1, MMP8 and MMP13 as diagnostic and
prognostic markers of breast cancer.
Methods: A total of 208 breast cancer patients, of which 21 with inflammatory breast cancer, and 42 healthy
controls were included. Plasma MMP1, MMP8 and MMP13 levels were measured using ELISA and correlated with
clinicopathological characteristics.
Results: Median plasma MMP1 levels were higher in controls than in breast cancer patients (3.45 vs. 2.01 ng/ml),
while no difference was found for MMP8 (10.74 vs. 10.49 ng/ml). ROC analysis for MMP1 revealed an AUC of
0.67, sensitivity of 80% and specificity of 24% at a cut-off value of 4.24 ng/ml. Plasma MMP13 expression could not
be detected. No correlation was found between MMP1 and MMP8 levels. We found a trend of lower MMP1 levels
with increasing tumour size (p = 0.07); and higher MMP8 levels with premenopausal status (p = 0.06) and NPI (p
= 0.04). The median plasma MMP1 (p = 0.02) and MMP8 (p = 0.007) levels in the non-inflammatory breast cancer
patients were almost twice as high as those found in the inflammatory breast cancer patients. Intriguingly, plasma
MMP8 levels were positively associated with lymph node involvement but showed a negative correlation with the
risk of distant metastasis. Both controls and lymph node negative patients (pN0) had lower MMP8 levels than
patients with moderate lymph node involvement (pN1, pN2) (p = 0.001); and showed a trend for higher MMP8
levels compared to patients with extensive lymph node involvement (pN3) and a strong predisposition to distant
metastasis (p = 0.11). Based on the hypothesis that blood and tissue protein levels are in reverse association, these
results suggest that MMP8 in the tumour may have a protective effect against lymph node metastasis.
Conclusion: In summary, we observed differences in MMP1 and MMP8 plasma levels between healthy controls
and breast cancer patients as well as between breast cancer patients. Interestingly, our results suggest that MMP8
may affect the metastatic behaviour of breast cancer cells through protection against lymph node metastasis,
underlining the importance of anti-target identification in drug development.
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Invasive breast cancer is one of the most common forms
of cancer in Europe. In women, breast cancer accounts for
29% of all cancers and is the major cause of cancer deaths
[1]. Currently, prognosis and choice of treatment is deter-
mined based on histologic tumour type, grade, tumour
size, lymph node involvement, steroid hormone receptor
expression and Her2 status. However, assessment of these
clinical and pathological features does not enable us to
fully capture the heterogeneous clinical course of breast
cancer [2]. Therefore, there is a continuous search for new
biomarkers of invasion and metastases.
Matrix metalloproteinases (MMPs) are a family of zinc
dependent endopeptidases that can degrade virtually all
extracellular matrix components [3]. Five MMP subgroups
are defined according to their substrate specificity and
domain structure: collagenases, gelatinases, stromelyins,
matrilysins and membrane-type MMPs. Both in physio-
logical and pathological conditions their expression is
rapidly induced when active tissue remodelling is needed.
It is well recognized that MMPs are key mediators of
tumour invasion and metastasis, being involved in cell
proliferation, survival, angiogenesis, and cell migration
[4]. Aberrant MMP expression has been observed to be
associated with prognosis in several types of carcinomas,
including breast cancer. Because tissue MMPs may enter
into the blood stream and increase circulating levels, it is
believed that MMP levels in the blood may serve as bio-
logical markers for disease onset or progression, and allow
monitoring of the disease. Several studies have evaluated
the diagnostic and prognostic value of circulating MMP2
and MMP9 in breast cancer because of their important
role in tumour invasion and metastasis. Elevated levels of
both MMP2 and MMP9 have been observed in blood
from breast cancer patients and were repeatedly found to
be associated with advanced stage, lymph node metastasis
and poor prognosis [5-15].
In this study, we evaluated the usefulness of circulating
MMP1, MMP8 and MMP13 levels as diagnostic and prog-
nostic markers in breast cancer. These MMPs form the col-
lagenase subgroup of MMPs, capable of cleaving native
fibrillar collagens (types I, II, III, and V) as well as various
non-collagenous molecules [16]. Upregulation of all three
MMPs has been demonstrated in several tumours [16-18].
As yet, however, little is known about their diagnostic and
prognostic value in tumours and blood from breast cancer
patients. We used plasma samples to determine circulat-
ing collagenase levels since an increasing number of
reports indicates that it is the most reliable source for
MMP quantification in blood. For instance, serum MMP2
and MMP9 levels are found to be 'artificially' higher than
plasma levels due to increased release from platelets and
leukocytes during coagulation [19]. Since MMP8 is
mainly synthesized and stored in neutrophils, serum
MMP8 levels may also be affected by blood sampling and
handling. In order to avoid unreliable results, we thus
determined the MMP1, MMP8 and MMP13 expression in
plasma. This study aimed to evaluate 1) the diagnostic
value of circulating MMP1, MMP8 and MMP13 in breast
cancer patients, 2) the prognostic value of plasma MMP1,
MMP8 and MMP13 in breast cancer by correlating their
levels with standard prognostic factors, 3) the diagnostic
value of circulating MMP1, MMP8 and MMP13 in inflam-
matory breast cancer which is characterized by a particu-
larly aggressive behaviour and poor prognosis [20].
Methods
Subjects
A group of 208 patients with invasive breast cancer, newly
diagnosed at the Multidisciplinary Breast Centre of the
University hospital Leuven between 2003 and 2007, were
prospectively recruited to this study. The study design was
approved by the Medical Ethical Committee of the Uni-
versity Hospital Leuven. Patient characteristics were
extracted from clinical files, tumour characteristics and
lymph node status were retrieved from the pathology
reports, and all data were eventually collected in one cen-
tral database. In order for patients to be included in the
study the presence and appropriate storage of plasma
samples at the time of diagnosis was required. Patients
with a history of cancer, bilateral cancer or Paget's disease
of the nipple were excluded from the study. Twenty one
patients of the study group presented with inflammatory
breast cancer at diagnosis and all received neo-adjuvant
treatment according to the standard treatment guidelines
of our institute at that time. Therefore, their data on
tumour size, histologic grade, steroid hormone receptor
expression, Human Epidermal growth factor Receptor 2
(Her2) status, Nottingham Prognostic Index (NPI) and
lymph node involvement were not included in the statis-
tical analyses as they may be affected by treatment. Non-
inflammatory breast cancer patients had not received any
treatment at the time of diagnosis. The study also included
42 age-matched healthy controls, attending the Blood
Transfusion Centre in Leuven.
Plasma samples
Blood samples were collected into EDTA coated plasma
collection tubes. Plasma was obtained by centrifugation at
1300 g for 10 min and stored at -80°C until use. All per-
sonal identifiers of healthy controls and patients were
removed prior to transfer of samples to the biobank of the
Multidisciplinary Breast Centre of Leuven.
Histology of primary tumours
Tumour tissue was snap-frozen in liquid nitrogen within
1 hour after surgery. Typing of primary tumours was per-
formed according to the WHO-classification while forPage 2 of 8
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nodes were examined with haematoxylin eosin using 3
sections per node and sentinel lymph nodes classified as
negative were additionally stained with epithelial mark-
ers. Immunohistochemical staining for the oestrogen
receptor (ER), progesterone receptor (PR) and Her2 was
performed on formalin-fixed paraffin-embedded 4 µm
thick tissue sections. Staining of the steroid hormone
receptors was semi-quantitatively evaluated using the
Allred score and samples with a score of 3 or more were
respectively defined ER or PR positive. The DAKO-Her-
cepTest scoring system was used to evaluate Her2 staining,
after which cases with an intermediary staining (2+) were
further analyzed by dual-colour Fluorescence in situ
Hybridization in order to distinguish true Her2 gene
amplification from polysomy 17.
Sandwich enzyme-linked immunoassays (sELISAs)
Plasma MMP1, MMP8 and MMP13 levels were measured
using specific sELISAs, detecting both the pro- and active
forms (GE Healthcare Europe GmbH, Munich, Germany
for MMP1 and MMP13; RnD Systems Europe Ltd., Abing-
don, United Kingdom for MMP8). Plasma samples were
allowed to thaw at room temperature just before use.
Samples were diluted 20-fold for MMP8 analysis, while
for MMP1 and MMP13 measurements undiluted plasma
was used. Not all plasma samples were examined for
MMP1, MMP8 as well as MMP13 due to sample volume
deficiency or technical problems with some samples.
Measurements were done in duplicate and results were
expressed as median (interquartile range).
Statistical analysis
Assumption of normality was verified using the normal
probability plot, Shapiro-Wilk's W test and the Levene's
test for homogeneity of variances. None of the plasma col-
lagenase levels were found to be normally distributed.
Measurements were done in duplicate and results were
expressed as median, 1st and 3rd quartile or interquartile
range. The Mann-Whitney U test and Kruskal-Wallis test
were used to assess differences in plasma MMP1 and
MMP8 levels between healthy controls and patients as
well as between different patient groups. Odds ratios
(OR) were also calculated for the latter. Correlations were
evaluated using Spearman rank correlation coefficients.
The diagnostic values of plasma collagenase levels for
breast cancer were evaluated by receiver-operating charac-
teristics (ROC) analysis. All statistical analyses were car-
ried out using the software package SAS 9.1.3 service pack
4, the level of significance being set at α = 0,05.
Results
Subject characteristics
In total 208 patients were included in the study. Data for
MMP1 levels were unavailable for 6 patients and MMP8
data were unavailable for 10 patients, due to insufficient
sample volume or technical problems. The mean age at
diagnosis was 57 years (min-max; 28–86). Seventy four
(36%) patients were premenopausal, 123 (59%) post-
menopausal and for 11 (5%) patients menopausal status
was unknown.
Twenty one (10%) patients had inflammatory breast can-
cer and were not included for association analyses of
tumour size, histologic grade, lymph node involvement,
steroid hormone receptor status, Her2 expression and NPI
value. Most non-inflammatory carcinomas were classified
pT1 (43%; 81/187) or pT2 (42%; 78/187), and only a
minority was categorized as pT3 (15%; 28/187). Half
(53%; 99/187) of all tumours were poorly differentiated,
38% (71/187) moderately and 9% (17/187) well. A total
of 48% (89/187) of all patients were free of lymph node
metastasis, 36% (68/187) were affected to the extent of
stage pN1, 10% (19/187) to pN2 and 6% (11/187) to
pN3. Of all 187 non-inflammatory breast tumours, 12%
(22/187) were ER negative, 88% (165/187) ER positive,
18% (33/187) PR negative and 82% (153/187) PR posi-
tive. The vast majority (87%; 163/187) of all tumours
showed no overexpression of Her2.
Plasma collagenase levels in patients and healthy controls
Median plasma MMP1 levels were significantly higher (p
= 0.0005) in healthy controls (3.45 ng/ml, interquartile
range IQR 2.42–4.17 ng/ml) than in breast cancer patients
(2.01 ng/ml, IQR 0.79 – 3.71 ng/ml). A ROC curve was
generated for further analysis of the diagnostic value of
MMP1, as presented in Figure 1. The area under the curve
(AUC) was 0.67 (95% confidence interval 0.60 – 0.75),
with a sensitivity of 80% and specificity of 24% at a cut-
off value of 4.24 ng/ml. The highest diagnostic accuracy,
defined by a minimal number of false negative and false
positives, was found at a cut-off value of 2.40 ng/ml with
a sensitivity of 56% and specificity of 76%. No difference
in MMP8 levels was found between controls (10.74 ng/
ml, IQR 7.47 – 15.3 ng/ml) and patients (10.49 ng/ml,
IQR 4.22 – 18.93 ng/ml), the lack of diagnostic value of
plasma MMP8 was confirmed by ROC analysis with a
AUC of 0.53 (data not shown).
Plasma MMP1 and MMP8 levels did not correlate among
controls (rs = 0.10, p = 0.54, data not shown) nor among
breast cancer patients (rs = 0.009, p = 0.90, data not
shown).
Plasma MMP-13 levels could not be determined because
they did not reach the detection sensitivity of the assay in
both breast cancer patients and controls.Page 3 of 8
(page number not for citation purposes)
BMC Cancer 2008, 8:77 http://www.biomedcentral.com/1471-2407/8/77Plasma MMP1 and MMP8 expression in relation to 
clinicopathological parameters
The associations of plasma MMP1 and MMP8 levels with
various clinical and pathological variables are presented
in Table 1. We observed a trend of lower plasma MMP1
levels with increasing tumour size (Odds ratio OR 1.11, p
= 0.07) and found significantly lower MMP1 expression
in patients with inflammatory breast cancer (OR 0.74, p =
0.02, Figure 2a).
Likewise, the median value of plasma MMP8 levels in the
population of non-inflammatory breast cancer patients
was almost twice as high as those found in the inflamma-
tory breast cancer group (OR 0.90, p < 0.01; Figure 2b).
Further, elevated MMP8 levels weakly correlated with an
increasing NPI value (p = 0.04, rs = 0.16; data not shown),
and showed a trend with premenopausal status (OR 0.98,
p = 0.06). We found an interesting relation between
plasma MMP8 levels and lymph node invasion or the risk
of distant metastasis. MMP8 levels in controls and lymph
node negative patients (pN0) were lower than those in
patients with moderate lymph node involvement (pN1,
pN2); but higher than those in patients with extensive
lymph node metastasis (pN3) and a high risk of distant
metastasis, illustrated in Figure 3.
Discussion
Several studies have reported on the prognostic value of
serum and plasma MMP levels in breast cancer. However,
this study is, to our knowledge, the first to discuss the
prognostic potential of circulating collagenases in breast
cancer. The present study clearly demonstrates differences
in total MMP-1 and MMP-8 levels in plasma from patients
with different clinical and pathological characteristics.
Circulating MMP-13 levels did not reach the sensitivity
detection limit of the immunoassay and were not further
analyzed. MMP-13 plays a key role in collagen remodel-
ling and as such is believed to be involved in local inva-
sion rather than in metastasis formation. It is therefore
likely that MMP13 resides in the tumour microenviron-
ment in both early and advanced cancer stages, resulting
in low to very low levels entering the circulation.
We found lower plasma MMP1 levels in breast cancer
patients than in healthy controls. ROC analysis revealed a
AUC of 0.67 with a sensitivity of 80% and specificity of
24% at a cut-off value of 4.24 ng/ml plasma MMP1. This
high sensitivity rate suggests that plasma MMP1 may be a
good candidate biomarker for breast cancer. Unfortu-
nately, the low specificity of 24% hampers the clinical use
of circulating MMP1 due to significant overtreatment of
healthy individuals. Nevertheless we cannot exclude that
plasma MMP1 measurement in combination with assess-
ment of other candidate or established biomarkers may
improve breast cancer diagnosis. Furthermore, we
observed lower MMP1 levels in plasma from patients with
inflammatory breast cancer, a rare but very aggressive dis-
ease, and non-inflammatory breast cancer patients with
larger tumours. This seems to be in clear contradiction
with previous results demonstrating a clear correlation
between MMP1 overexpression and poor prognosis. How-
ever, it is not clear yet whether MMPs in blood and body
fluids exert any physiological function. Altered MMP lev-
els in blood may simply reflect local changes in the extra-
cellular microenvironment. Thus, we hypothesize that the
lower MMP1 levels observed in plasma could reflect a
concentration of MMP1 in the tumour microenviron-
ment. As such, the reverse correlation of plasma MMP1
with breast cancer risk and prognosis is to be expected. For
instance, the reverse correlation of plasma MMP1 expres-
sion with tumour growth is then in accordance with the
established tumour growth promoting role of MMP1 in
the tumour tissue [21].
We found a trend for higher plasma MMP8 levels in pre-
menopausal patients (p = 0.06). Further, we observed a
weak positive correlation (rs = 0.16, p = 0.04) of plasma
MMP8 with the Nottingham Prognostic Index which is
calculated based on the tumour size, differentiation grade
and lymph node status. Since plasma MMP8 did not sig-
nificantly correlate with either of these parameters, the
statistical significance of its relation with the NPI most
probably results from a type I error. If we assume, as for
MMP1, that the higher plasma MMP8 levels reflect a lower
expression in the tumour tissue; then the positive relation
Receiver-operator curves for plasma MMP1 levels, with AUC of 0.67Figure 1
Receiver-operator curves for plasma MMP1 levels, with AUC 
of 0.67.Page 4 of 8
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earlier onset, supports the notion of a protective role of
MMP8 in cancer [22-25]. The anti-tumorigenic and anti-
metastatic role emphasizes the notion that the role of
MMP8 in cancer is far more puzzling than originally
thought. Traditionally, MMP8 was considered to promote
tumour invasion and metastasis in accordance with the
general view on MMPs in cancer. In line with this, ele-
vated levels of MMP8 expression have been observed in
head and neck squamous cell carcinomas [26]. In ovarian
cancer, MMP8 expression has been associated with
tumour grade and stage, as well as with poor prognosis
[27,28]. The lower MMP8 levels observed in plasma of
patients with inflammatory breast cancer, which may
reflect higher levels in the tumour, are consistent with a
pro-tumorigenic role of MMP8 and suggest that MMP8
may be implicated in the inflammation-dependent mech-
anisms of this aggressive breast tumour type.
Table 1: Plasma MMP1 and MMP8 levels in relation to standard prognostic markers.
Characteristics MMP1 (ng/ml) OR (95% CI) p* MMP8 (ng/ml) OR (95% CI) p*
Median (IQR) n Median (IQR) n
all patients 2.0 (0.8–3.7) 202 10.5 (4.4–19.1) 198
menopausal status
premenopausal 2.0 (0.5–4.0) 70 1.02 (0.91–1.13) 0.67 14.8 (5.4–20.8) 70 0.98 (0.95–1.00) 0.06
postmenopausal 2.0 (1.0–3.5) 122 10.0 (4.2–18.8) 117
unknown 2.2 (1.3–3.0) 10 6.0 (3.6–13.4) 11
breast cancer
inflammatory 1.1 (0.6–2.0) 21 0.74 (0.56–0.98) 0.02 6.3 (3.5–8.5) 19 0.90 (0.83–0.97) 0.007
non-inflammatory 2.2 (0.8–3.9) 181 11.0 (4.7–20.5) 179
non-inflammatory breast cancer patients
Primary tumour size
pT1 2.4 (1.1–4.2) 79 1.11 (1.00–1.23) 0.07 10.2 (3.8–20.5) 76 0.99 (0.97–1.01) 0.14
pT2 2.2 (0.8–3.7) 76 11.0 (4.6–18.8) 77
pT3 1.3 (0.6–2.2) 26 16.4 (6.4–24.0) 26
axillary lymph node status
pN0 2.3 (1.1–4.1) 86 1.04 (0.94–1.15) 0.18 7.5 (3.5–19.1) 83 0.99 (0.97–1.01) 0.003
pN1 1.9 (0.8–3.6) 67 13.4 (8.0–22.5) 66
pN2 0.9 (0.1–3.4) 19 18.0 (12.5–22.0) 19
pN3 2.7 (1.9–4.6) 9 5.7 (2.9–8.9) 11
histologic grade
well (G1) 3.4 (1.0–4.6) 17 0.99 (0.90–1.10) 0.14 4.9 (3.3–20.9) 16 1.00 (0.98–1.03) 0.37
moderatly (G2) 1.6 (0.6–3.0) 70 15.2 (4.8–21.6) 68
poorly (G3) 2.2 (1.1–4.0) 94 11.0 (5.4–18.9) 95
oestrogen receptor
Negative 1.6 (0.2–3.7) 21 1.13 (0.92–1.39) 0.31 8.9 (4.3–22.9) 22 1.00 (0.97–1.04) 0.93
Positive 2.2 (0.9–4.0) 160 11.3 (5.1–20.1) 157
progesteron receptor †
Negative 2.0 (0.2–3.5) 32 1.13 (0.95–1.35) 0.29 12.3 (4.9–23.5) 32 0.98 (0.95–1.00) 0.30
Positive 2.2 (0.9–4.0) 148 10.9 (4.7–19.4) 146
Her2 overexpression
Negative 2.2 (0.8–3.8) 158 0.97 (0.82–1.14) 0.79 10.9 (4.9–20.2) 156 1.03 (1.00–1.06) 0.39
Positive 1.8 (1.1–4.4) 23 13.7 (3.2–25.7) 23
*p for Mann-Whitney U test or Kruskal-Wallis test. † Progesteron receptor status is unknown for one patient in both MMP1 and MMP8 analyses.
Note: Her2 status was defined by immunohistochemistry and dual-colour FISH analyses
IQR, interquartile range; OR, odds ratioPage 5 of 8
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MMP8 levels with lymph node metastasis and the risk of
distant metastasis. Similar MMP8 expression was found in
plasma from healthy controls and breast cancer patients
without lymph node involvement (pN0). The median
MMP8 levels in controls and lymph node negative
patients (pN0) were significantly lower than in patients
with moderate lymph node involvement (pN1, pN2); but
higher than in patients with extensive lymph node metas-
tasis (pN3) and a strong predisposition to distant metas-
tasis. Based on the hypothesis of reverse association of
tissue and blood MMP levels, these results support the
anti-metastatic role for MMP8 and may even indicate that
MMP8 has a greater protective effect against lymph node
metastasis as compared with distant metastasis. This
hypothesis has been put forward by Montel and col-
leagues who recently reported that reducing MMP8 levels
by the ribozyme knock-down technique dramatically
increased lymph node metastasis of breast cancer cells
orthotopically implanted in mice but has a smaller effect
on metastasis to the lung [24]. In our study, we observed
that 1) higher plasma/lower tumour tissue MMP8 levels
were more often found in patients with moderate lymph
node involvement and that 2) lower plasma/higher
tumour tissue MMP8 levels were more common in
patients with pN3 breast disease which is strongly associ-
ated with systemic disease. Thus, our results support the
data from Montel and coworkers in the observation that
MMP8 overexpression in the tumour protects against
lymph node metastasis but not against distant metastasis.
Moreover, our data indicate that MMP8 overexpression
may even have an adverse influence on distant metastasis
and may predispose cancer cells to spread by the haema-
togenous route. This complex association of MMP8 with
metastasis may explain why we did not find any signifi-
cant difference in plasma MMP8 levels between healthy
controls and the overall breast cancer group. Nevertheless,
it seems unlikely that changes in MMP8 expression alone
could affect the metastatic behaviour of cancer cells so
dramatically. It is more likely that significant changes in
MMP8 expression perturb the constant flux of the pro-
Differences in plasma levels of A) MMP1 and B) MMP8 between patients with and without inflammatory breast cancer (box-whisk r diagrams with m dian, 1st quartile, 3rd quartile and non-outlier range)Figu  2
Differences in plasma levels of A) MMP1 and B) MMP8 between patients with and without inflammatory breast cancer (box-
whisker diagrams with median, 1st quartile, 3rd quartile and non-outlier range).
Association of plasma MMP8 levels with the extent of lymph node metastasis nd risk of distant metastasisFigure 3
Association of plasma MMP8 levels with the extent of lymph 
node metastasis and risk of distant metastasis. note: controls 
+ pN0 comprises healthy women and breast cancer patients 
without detectable lymph node or distant metastasis; 
pN1+pN2 comprises patients with moderate lymph node 
metastasis but without distant metastasis; pN3 comprises 
patients with extensive lymph node metastasis and a high risk 
of distant metastasis (box-whisker diagrams with median, 1st 
quartile, 3rd quartile and non-outlier range).Page 6 of 8
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classes, families and pathways. Overexpression of one
protease may significantly perturb the web, forging new
web connections that lead to new, unpredictable activities
that may promote or inhibit tumour progression and
metastasis [29].
Conclusion
In conclusion, the present study led us to formulate the
hypothesis that blood MMP levels reflect local changes in
MMP expression in the tumour microenvironment so that
inverse associations are to be expected. Our results sup-
port previous data, suggesting a tumour-promoting role
for MMP1 in breast cancer. Moreover, the present data
exemplify the puzzling dual role of MMP8 in breast cancer
as both pro- and anti-tumorigenic/metastatic. Interest-
ingly, we found that MMP8 may affect the metastatic
behaviour of breast cancer cells and may be implicated in
directing organ-specific metastasis. As MMPs have also
important functions in normal tissue homeostasis, one of
the challenges in combating cancer metastasis by MMP
inhibition is to determine which MMPs are clearly anti-
targets. Blocking MMP anti-targets might counterbalance
the beneficial effects of target inhibition and have a detri-
mental influence on patient outcome and mortality,
thereby contributing to the failure of MPI clinical trials.
Therefore, further investigation with larger patient cohorts
is clearly needed to better understand the paradoxical role
of MMP8 in cancer metastasis.
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